CTI BioPharma Corp. (CTIC) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Seattle, WA, United States. The current CEO is Adam R. Craig.
CTIC has IPO date of 1997-03-21, 127 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $1.2B.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
